The first meeting of the Chinese expert working group of the 2012 China US pharmaceutical industry summit was successfully held

Source: on April 11, 2012, in order to serve the 2012 China US pharmaceutical industry summit and make team preparation and theoretical preparation for the summit, the first meeting of the Chinese expert working group of 2012 China US pharmaceutical industry summit organized by China Pharmaceutical Council was held in Kaiyuan Hotel, Gehua, Beijing on the morning of April 10 The experts attending the meeting are: Professor Shao Rong, Dean of the school of international medicine business of China Pharmaceutical University, Professor Wu zhiang, Dean of the school of Business Administration of Shenyang Pharmaceutical University, Professor of the school of medicine of West China Medical Center of Sichuan University, Professor Song Min Xian, former Registrar of Sichuan Provincial Drug Administration, and professors from China Pharmaceutical Corporation, Yangzijiang Pharmaceutical Group, Petrochemicals Group and Shanghai Representatives of nearly 20 enterprises in charge of drug registration, such as Fosun, Shanghai Pharmaceutical Group, Xiansheng pharmaceutical, LVYE Pharmaceutical Group, Zhejiang Beida pharmaceutical, Shenzhen OSA, Shenyang Sansheng and Baiji Shenzhou, attended the meeting as members of the Chinese expert working group Song Ruilin, executive chairman of China pharmaceutical promotion association, presided over the meeting The meeting focused on the current situation of China's drug registration and approval policies and regulations, the current difficulties of China's innovative drugs in the registration and approval, the U.S drug registration and approval management system and its reference to China, and the Discussion on the contents to be negotiated between China and the United States at this year's China US pharmaceutical industry summit Chen Changxiong, Executive Deputy Secretary General of China Association for the promotion of drugs, made a brief introduction to the research work carried out in the early stage of China Association for the promotion of drugs, Professor Wu zhiang introduced several nodes to be grasped in the revision of China's innovative drug approval system, President Wang Yinxiang of Zhejiang Beida Pharmaceutical Co., Ltd introduced the latest development of China's drug registration review, and Dr Tian Hong of Baiji Shenzhou company introduced the new drug registration law of the United States Regulatory system and review procedures Subsequently, the participants had a heated discussion on the drug registration laws and regulations of China and the United States, and the contents to be negotiated in the meeting of the working group of experts of China and the United States, and determined the key Chinese speakers of the meeting At the end of the meeting, song Ruilin, executive chairman of China Council for the promotion of drugs, summarized the discussion results of relevant issues and determined the next work arrangement The meeting was a complete success Through this working group meeting, members of the Chinese expert working group expressed their opinions on the topic of drug innovation, and reached a consensus that China needs to use the system to solve the problem of innovative drug review This meeting laid a good foundation for the successful holding of the China US working group meeting in May and the fourth China US pharmaceutical industry summit Brief introduction of Executive Deputy Secretary General Chen Changxiong of China Council for the promotion of drugs on the spot